The effect of endothelin-1 (ET-1) on the proximal tubule remains unclear. This may be due to a biphasic effect on transport in this segment. We hypothesized that ET-1 has a biphasic effect on fluid absorption (Jv) in the proximal straight tubule and that its inhibitory effect is superimposed on its stimulatory effect. ET-1 (10-13 M) stimulated Jv from 0.68±0.07 to 1.11±0.20 nl/mm/min, a 60% increase (P < 0.04). 10-12 and 1010 M ET-1 had no significant effect. 10-' M ET-1 reduced Jv from 0.81±0.19 to 0.44±0.15 nl/mm/min (P < 0.009).
Introduction
While the vasoconstrictor endothelin (ET-1)' has been extensively studied in a variety of tissues ( 1, 2, 3) , its action and second messenger pathway in the proximal tubule are not entirely clear. ET-1 has been reported to be both antinatriuretic methacin; Jv, fluid absorption; LT, leukotrienes; PKC, protein kinase C; PL, phospholipase; PST, proximal straight tubule; QNC, quinacrine; STP, staurosporine.
(4) and natriuretic (5, 6) . The antinatriuresis may have been due to decreases in glomerular filtration and renal blood flow whereas the natriuretic effect was independent of its action on renal hemodynamics indicating that endothelin acts directly on the nephron. There is in vivo evidence for both proximal and distal nephron effects. Perico et al. (5) reported that this effect is only on the proximal tubule; while other in vivo data indicate that ET-1 induces natriuresis and diuresis to direct action of the peptide in both the proximal and distal nephron (6) .
In addition to the in vivo data there is in vitro data concerning an effect of ET-1 on the proximal nephron. Garvin and Sanders (7) using isolated, perfused rat proximal straight tubules (PST) reported that 10-9 M ET-1 inhibited fluid absorption (Jv), consistent with the natriuretic effects reported by Perico et al. (5) and Harris et al. (6) . In contrast, Eiam-Ong et al. (1) reported only increased Na+ transport with 10-8 to 10 " M ET-l using basolateral and brush border membrane vesicles. This effect was dependent on activation of Na+/H+ exchange and Na+/HCO-cotransport. Additionally, Guntupalli et al. (8) , using brush border membrane vesicles, found that 10-9to 10-" M ET-l increased Na+/phosphate and Na+/ H+ transport while l0-7 M ET-l inhibited them. Finally, Zeidel et al. (9) reported that oxygen consumption in the proximal convoluted tubule, and consequently sodium transport, was not affected by ET-1. The disparate results may be due to the biphasic effect of endothelin.
In light of the ambiguity regarding the effect of endothelin on transport, it is not surprising that data concerning the second messenger cascade are also conflicting. Guntupalli et al. (8) concluded that both the inhibition and stimulation oftransport induced by ET-1 are due to the participation ofphospholipase (PL) C and protein kinase C (PKC). In contrast, Perico et al. (5) showed that oral administration of a specific 5-lipoxygenase inhibitor (L-651,392) in rats prevented the increased urine flow rate and absolute and fractional sodium excretion caused by a single i.v. bolus of 0.3 ml of ET-1 administered over 1 Fluid absorption (Jv) was measured using raffinose as a volume marker. Raffinose was measured in the perfusate and collected fluid using a previously described enzymatic assay with a continuous-flow ultramicrofluorometer (12) . The (10-4 M) and in ETI (10-6 M) plus indomethacin (10-' M) . Two-tailed tests were performed in the rest of the protocols. All experiments in which at least two measurements of Jv were made during each period were reported.
Results
To investigate whether ET-1 has a biphasic effect on Jv, intact isolated rat PSTs were incubated with different concentrations of ET-1 in the basolateral bath and Jv was measured. The effect of each concentration of ET-1 was examined in separate studies (Fig. 1) . When six PSTs were perfused at a rate of 4.89±0.34 nl/min/mm; Jv was 0.68±0.07 nl/min/mm. After we treated the tubules with l0-'3 M ET-1, Jv rose to 1.1 1±0.20 nl/min/mm, an increase of 60% (P < 0.04). Next we tested 10-12 M ET-1. During the control period Jv in four tubules was 1.09±0.27 nl/min/mm. Jv was 1.22±0.32 nl/min/mm after ET-1 was added to the bath, a small and insignificant increase. ET-I has a biphasic effect on fluid absorption in intact isolated rat proximal tubules.
PKC has been implicated as a mediator of ET-l's effect in several tissues (2, 3, 13) and a mediator of Na+/H+ exchange activity in proximal tubule cells (8, 14, 15, 16) . Since both stimulation and inhibition of Na+/H' exchange by ET-l is reportedly dependent on activation of PKC (8), we tested whether suppression of PKC would influence both effects of ET-1 on Jv. The PKC inhibitor staurosporine (STP; 10-8 M) was added to the bath at the beginning ofthe incubation period and maintained for the duration of the experiment. (Fig. 2) . STP alone did not change Jv significantly. Time controls with STP present from the start showed no change in Jv. These data indicate that both the stimulatory and inhibitory effects ofET-1 are dependent on activation of PKC.
Since the increase in Jv induced by ET-1 is readily explained by PKC directly stimulating Na+/H + exchange activity ( 14, 15), we did not pursue the mechanism of the stimula- tion further. The mechanism whereby ET-1 could inhibit Jv by activating PKC is less clear. However, PKC can activate phospholipase A2 and D ( 17) , and in this way could stimulate prostaglandin synthesis. Prostaglandins have been shown to inhibit fluid absorption in the proximal nephron ( 18) and ET-l-induced inhibition of Na' transport in the collecting duct is due to prostaglandin release (9) . Consequently, we investigated whether prostaglandins mediate the inhibitory effect of I0-9 M ET-1 using the cyclooxygenase inhibitor, indomethacin (INDO, 10-5 M). INDO was added to the bath at the beginning of the incubation period and maintained for the remainder of the experiment. During the control period, eight proximal tubules were perfused at a rate of 3.98±0.53 nl/min/ mm in the presence of INDO; Jv was 0.62±0.16 nl/min/mm. When we added 10-9 M ET to the bath, Jv did not change significantly (P > 0.90) (Fig. 3) . INDO alone did not change Jv significantly from the control value (P > 0.70). Time controls with INDO present from the start showed no significant change in Jv (P > 0.70). From these data we concluded that cyclooxygenase products mediate ET-l's inhibition of Jv in the PST.
It is well known that arachidonic acid, the precursor of prostaglandins (PG) and leukotrienes, can be released by phospholipase (PL) A2 or D. To add further evidence that arachidonic acid is involved in the decrease in Jv caused by ET-1, we tested whether inhibition of PL A2 and D would block this effect. The PL D and A2 inhibitor quinacrine (QNC, l0-5 M) was added to the bath at the beginning ofthe incubation period and maintained for the duration ofthe experiment. During the control period, eight tubules were perfused at a rate of 4.54±0.58 nl/min/mm in the presence of QNC; Jv was 1.02±0.20 nl/min/mm. When we added 10-9 M ET-l to the bath, Jv surprisingly increased from 1.02±0.20 to 1.23±0. 22 nl/min/mm (P < 0.03) (Fig. 4) . QNC alone did not significantly affect Jv. Time controls with QNC present from the start showed no change in Jv. Thus blockade of PL D and/or A2 revealed a stimulatory effect of 10-9 M ET-1 on Jv.
To examine the possibility that stimulation ofJv by l0-9 M ET-1 in QNC-treated PSTs was due to the same mechanism as activated by 10-`3 M (i.e., activation of PKC), we incubated tubules in the presence of STP and QNC. Jv was 0.79±0.20 nl/min/mm during the control period with both inhibitors and 0.70±0.15 nl/mm/min after 10-' M ET-l was added to the bath, a value not significantly different from control (P > 0.40) (Fig. 5) . From these data we concluded that the stimulation of (n = 4, P < 0.05). This increase was similar to that seen in the presence of quinacrine. Because Perico et al. (5) reported that the natriuresis induced by ET-1 is mediated by leukotrienes (LT), and it is possible that at a concentration of 10-4 M indomethacin could be inhibiting enzymes besides cyclooxygenase, we investigated the ability of a selective LT D4 receptor antagonist, L-660,7 1 1 ( 11 ) , to block the effect of 10-9 M ET-1. When we perfused PSTs in the presence of L-660,711 and Jv was 0.63±0.06 nl/ min/mm. When ET-l 10-9 M was added, Jv decreased from 0.63±0.06 nl/min/mm to 0.31±0.06 nl/min/mm (P < 0.02). This decrease was similar to that found in the absence of the leukotriene receptor antagonist.
Next we blocked the synthesis ofleukotrienes with a lipoxygenase inhibitor, ETI (10-6 M). ETI was added to the bath at the beginning of the incubation period and maintained for the 0.
-remainder of the experiment. During the control period, PSTs were perfused at a rate of 3.16±0.35 nl/min/mm in the presence of ETI; Jv was 0.73±0.15 nl/min/mm. When we added I0-9 M ET to the bath, Jv did not change significantly (P > 0.60). ETI alone did not change Jv significantly from the control value (P > 0.60). From these data we concluded that the inhibition induced by ET-I is mediated, in part, by lipoxygenase products.
To examine if the stimulatory effect induced by ET-1 10-9 M in QNC-treated tubule was due to the blockade of PG and LT production, we incubated proximal straight tubules in the presence of both inhibitors, INDO (10-' M) and ETI M). In the presence of both inhibitors when I0 -M ET-1 was added, Jv increased by 16 .5% (P < 0.05). Indomethacin and ETI together did not change fluid absorption from the control value (P > 0.70). From these data we concluded that both cyclooxygenase and lipoxygenase products are responsible for the inhibitory effects of 10-9 M ET-1. When both pathways are blocked, a stimulatory effect is revealed.
Discussion
The effects of endothelin on the proximal tubule and the second messenger system(s) involved are unclear. We found that ET-1 had a biphasic effect on Jv. The stimulatory effect was mediated by activation of PKC. Interestingly, the inhibitory effect was also mediated by activation of PKC and dependent on PL, cyclooxygenase, and lipoxygenase activity.
Since Yanagisawa et al. ( 19) reported the vascular effect of endothelin, there have been several investigations into its renal actions. Intravenous infusion ofendothelin (50 ng/kg/min) in dogs has been reported to be antinatriuretic (4); however, this antinatriuretic effect was due to a marked reduction in both renal blood flow and glomerular filtration rate. A single i.v. bolus of 75-150 pmol of ET-l administered over 1 min to rats caused diuretic and natriuretic effects that were independent of its action on renal hemodynamics (5). These effects were dependent on a direct action in the proximal tubule as determined by lithium clearance. Other in vivo data indicate that infusion of 1 and 10 ng/kg/min endothelin induces natriuresis and diuresis in anesthetized rats (6). Endothelin significantly increased both fractional sodium excretion and lithium clearance. The increase in lithium clearance only partially accounted for the increase in fractional sodium excretion, indicating that the natriuresis was due in part to direct action ofthe peptide on the proximal tubule and in part to other segments. In an attempt to clarify this issue, assess the role ofthe proximal nephron in this response, and address the issue of the second messenger(s) involved, we examined the effects of different concentrations ofET-1 on fluid absorption in the isolated, perfused rat proximal straight tubule.
In this study ET-1 had a biphasic effect on fluid absorption in isolated, perfused rat proximal straight tubules. ET-1 increased fluid absorption by 60% at a concentration of IOl M, while at 10-12 M stimulation was less marked. ET-l had no effect on fluid absorption at 1010 M and actually inhibited it by 50% at 10-1 M. The inhibitory effect of ET-l on fluid absorption is consistent with previously published data from our laboratory which showed that l0-9 M ET-1 decreased fluid absorption in the proximal tubule also by 50% (7) .
The biphasic effect of endothelin is not unique to this hormone or preparation. A similar biphasic effect has been reported for the response ofthe proximal nephron to angiotensin II (20, 21) . Endothelin has also been reported to have a biphasic effect on cultured lactotrophs (22) . A similar effect was demonstrated in rat brush border membrane vesicles, although the dose-response curve was shifted toward higher concentrations. 10-9 to 10-" M ET-1 increased Na+/phosphate transport by 52% and Na+/H+ exchange activity by 81%, whereas 10' M decreased the activity of both transporters (8) . The apparent difference in the dose-response relationship between isolated, perfused proximal tubules and brush border membrane vesicles may be due to the fact that in our study ET-1 was added to the basolateral bath as opposed to being exposed to the luminal membrane. This difference in protocols raises the possibility that either the receptors on the luminal and basolateral membranes differ or that in the study using brush border membrane vesicles the actual endothelin concentration was lower than that reported due to the presence of proteases in the luminal membrane. The proximal nephron brush border membrane is rich in proteases (23), and breakdown ofendothelin by such enzymes has been documented (24, 25) . The use of proteinase inhibitors in brush border membrane vesicle experiments could address this issue. In contrast to the biphasic effect of endothelin on transport noted above, Eiam-Ong et al. (1), using brush border membrane vesicles from rabbits, described only a stimulatory effect of 10-8 to 10'-1 M ET-1. Their inability to demonstrate a biphasic effect may be due to either the presence of proteases as described above or a true species difference.
Although several investigators have reported an effect of ET-1 on transport processes in proximal tubule preparations, there have also been several reports which seem to indicate that ET-l does not affect the proximal nephron (9, 26, 27) . While the cause ofthis is not absolutely certain, there are likely explanations for the discrepancy. The report that there was little or no specific 1251 endothelin binding data may have been due to insufficient specific activity of the endothelin, which could detect the large number of receptors in the inner medullary collecting duct, but not in all segments of the proximal nephron. Low but significant binding was found in S 1 (27) . The inability of Terada et al. (26) to find ET-1 receptor mRNA is likely due to the low number ofmRNAs for membrane-bound receptors or use of tissue in which the message was degraded. Finally, the report that ET-1 does not affect oxygen consumption may simply have been due to use of a dose that does not affect transport greatly, i.e., 10-12 through 1010 M (9) . What ever the explanation for the negative results, they in no way alter the importance of the findings of this paper or those which show that ET-l can effect proximal nephron transport. Physiologically, the effect of ET-1 on the proximal nephron may be of great significance, since the proximal nephron absorbs 60-70% of the filtered sodium while the collecting duct only absorbs 6%.
The stimulation of Jv induced by I0'1 M ET-1 was inhibited by staurosporine, indicating that it involved the activation of PKC. The participation of PKC in endothelin's effect has been described for other tissues such as smooth muscle (28) using different inhibitors or downregulation of protein kinase C (2) . ET-Is role in PKC activation was also described in rat brush border membrane vesicles, where staurosporine inhibited the endothelin-induced stimulation of both Na+/H' and Na+/phosphate transporters (8 shown to be part of the second messenger cascade whereby angiotensin II stimulates fluid absorption in the proximal nephron (19) . Simonson et al. (13) reported that 10-13 M ET-1 stimulated phospholipase C activity and increased intracellular calcium levels and presumably PKC in cultured rat messangial cells. This effect was followed by activation ofNa+/ H+ exchange as measured by alkalinization of intracellular pH ( 16) .
Interestingly, we also found that the inhibitory effect of endothelin was blocked by staurosporine, indicating that activation of PKC is also involved in the endothelin-induced inhibition offluid absorption. PKC has been described as an inhibitor of Na+/K' ATPase activity in the proximal tubule as part of the signaling system used by dopamine (29) ; however, it is not clear whether PKC was acting directly or through some other enzyme(s). It is unlikely that PKC was acting directly to inhibit Na+/K+ ATPase in our experiments, since the inhibition could be blocked by quinacrine, indomethacin and ETI; steps subsequent to activation of PKC. PKC activation in the endothelin-induced inhibition ofboth Na + / H + and Na+/phosphate transporters (8) was also described in rat brush border membrane vesicles where there is no Na+/K' ATPase.
In this study we found that the inhibition of fluid absorption induced by endothelin could be blocked by inhibiting either phospholipase A2 and/or D, cyclooxygenase or lipoxygenase. These experiments indicate that release ofarachidonic acid is vital to ET-l's inhibitory effect. Additionally, we show that subsequent production of prostaglandins and leukotrienes by the fore-mentioned enzymes can account for the inhibitory effect. A role for prostaglandin in the inhibition is not surprising. Prostaglandins have been shown to inhibit transport in the proximal nephron (18) , MDCK cells (30) , and the cortical collecting duct (31) . Endothelin has also been reported to activate phospholipase A2 in several tissues, leading to the release of arachidonic acid which is then metabolized to prostaglandins, thromboxanes, or leukotrienes (3).
The participation of lipoxygenase metabolites in ET-induced natriuresis and diuresis was previously described in vivo by Perico et al. (5) ; however, they did not examine ifcyclooxygenase activity was also essential to this process. Perico et al. (5) also reported that the effects ofendothelin could be blocked by a leukotriene D4 receptor antagonist. We found that leukotriene D4's do not participate in the inhibitory effect induced by ET-1, but that inhibition of the production of leukotrienes by blockade of lipoxygenase activity blocked the ET-1-induced inhibition of Jv.
Data from Stier et al. (32) , using an isolated, perfused rat kidney, show that the effect ofET-3 on renal function were not modified by pretreatment with indomethacin indicating that prostaglandin were not involved. However, these results do not necessarily conflict with ours, since ET-3 has been shown to act via a different mechanism than ET-1 in vascular smooth muscle cells (33) .
In proximal straight tubules pretreated with quinacrine we found that 10-9 M ET-1 increased fluid absorption significantly indicating that inhibition is superimposed on stimulation. This stimulation was also observed in when 10 -4 M indomethacin was present or when both 10 -5 M indomethacin and ETI were present. These data seem to indicate that: (a) both inhibitory cyclooxygenase and lipoxygenase products are produced when 10-9 M ET-1 is present and that blocking only one pathway is insufficient to completely prevent the inhibitory effect; and 2) 1-0 M indomethacin may inhibit lipoxygenase as well as cyclooxygenase activity.
The stimulation of Jv produced by ET-1 in quinacrinetreated tubules was blocked by an inhibitor ofPKC. In tubules pretreated with both quinacrine and staurosporine, 10-9 M ET-1 had no effect on fluid absorption. Consequently we concluded that protein kinase C activates either phospholipase A2 and/or D. The ability ofPKC to stimulate phospholipase activity and release arachidonic acid has been reported to occur in cortical collecting tubular cells treated with bradykinin (34) .
From our results, we propose the following cascade for the bimodal effect of ET-1 on fluid absorption. First, the stimulatory effect produced by I0--3 M ET-l is a result ofactivation of phospholipase C and consequent activation of PKC. Activation ofPKC in this model increases fluid absorption. The inhibitory effect of ET-1 is a result of further activation of both phospholipase C and PKC. This higher level ofPKC activation causes stimulation of phospholipase A2 and/or D. Activation of one or both phospholipases releases arachidonic acid. The arachidonic acid is metabolized into prostaglandin and leukotrienes, whose in turn inhibit fluid absorption.
